
    
      It is a randomized, double-blind, placebo-controlled trial, about 324 nasopharyngeal
      carcinoma (NPC) patients will be enrolled from six centers in Guangdong Province and
      randomized 1:1 to atorvastatin group (20mg per night, totally 2 years) or placebo group. All
      Patients will be followed up for 2 years. Ultrasound and Transcranial Color Doppler (TCD)
      will be used to evaluate the changes of intima-media thickness (IMT) and occurrence of plaque
      formation of carotid arteries. Safety will be monitored every 6 months.
    
  